Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL INTENSOL versus PROCHLORPERAZINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOPERIDOL INTENSOL versus PROCHLORPERAZINE MALEATE.
HALOPERIDOL INTENSOL vs PROCHLORPERAZINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol is a typical antipsychotic that primarily antagonizes dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also has moderate affinity for alpha-1 adrenergic receptors and low affinity for H1 histamine and muscarinic cholinergic receptors.
Prochlorperazine is a phenothiazine antipsychotic that primarily antagonizes dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and central nervous system. It also has anticholinergic and antiemetic effects through blockade of histamine H1 and muscarinic M1 receptors.
Oral (Intensol): 0.5-5 mg twice or three times daily. Maximum: 100 mg/day.
5-10 mg orally 3-4 times daily; or 25 mg rectally twice daily; or 5-10 mg intramuscularly every 3-4 hours up to 40 mg/day; or 2.5-10 mg intravenously slowly at 2.5 mg/min, maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14-37 hours (average 21 hours) after oral administration; may be longer in elderly or hepatic impairment.
Terminal elimination half-life is approximately 6-8 hours in adults, but may extend up to 12-15 hours after chronic dosing or in hepatic impairment.
Primarily hepatic metabolism with renal elimination of metabolites; about 40% excreted in urine and 15% in feces via bile.
Primarily renal (70-80% as metabolites, <1% unchanged); fecal/biliary excretion accounts for 20-30% via enterohepatic circulation.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic